5 Most Discussed Stocks – AVZ, BIT, PLS, MXC and A2M

Discussed Stocks Australia

While the markets slipped further down to 6,041 level, there were few stocks at the back of strong internal results, being talked about. Here is a peek into these stocks which are today’s most discussed ones.

AVZ MINERALS LIMITED (ASX: AVZ) – The revenue from continuing operations increased from $20,432 in 2017 to $169,121 in 2018. However, the total comprehensive loss of the year was $3,237,829 in 2018 which has increased from the prior corresponding period. The company reported the cash and cash equivalents at the end of the year June 30, 2018 was of $16.34 million with zero or no debt representing a decent balance sheet. As at October 9, 2018, the stock of AVZ Minerals is under the suspended status but last traded at a market price of $0.087 which is close to its 52-week low and expectations are of a rebound, it has seen a performance change of 17.70% since inception.

BIOTRON LIMITED (ASX: BIT) – The company’s strategy is to work towards a commercial outcome for shareholders and grow the value of the company. By way of an underwritten renounceable rights issue the company completed a capital raising of $1.4 million after costs in the second half of the financial year. The net loss after tax from ordinary activities were down by 48.48% to $1,593,645, resultant to which the board recommended not to declare any dividends during the current year or the previous financial year. However down from $1,987,384 in 2017, the cash and cash equivalents at the end of June 30, 3018 is of $1,543,002 which represented a healthy balance sheet. The stock of Biotron Limited traded at a market price of $0.125, as at October 9, 2018, and over the last twelve months period has seen a performance change of a staggering 543.08%.

PILBARA MINERALS LIMITED (ASX: PLS) – Between 14 September 2018 and 21 September 2018, the company was expecting the first shipment forecast to start. Compared to $25.9 Mn in FY17, the company saw a decline in loss of $19.1 Mn for FY 18. The first five years average EBITDA (real) post ramp up of A$400 M pa. The company has one of the best lithium raw material project in the world with low cost, long life and high quality. The company has a cash balance of A$120 million as at September 14, 2018. As at October 9, 2018, the stock of Pilbara Minerals traded at a market price of $0.835 and is expected to go down for the coming couple of days based on moving average, it has seen a performance change of 7.84% over the last twelve months period.  [optin-monster-shortcode id=”wxhmli4jjedneglg1trq”]

MGC PHARMACEUTICALS LIMITED (ASX: MXC) – As at June 30, 2018 quarter, the current cash and cash equivalent stands at $9.859 million. The revenue for the period ending June 30, 2018 increased to $296,811 from $120,242 on June 30, 2017. Due to slight increase in net loss for the year at $8,246,340 no dividends were paid or declared for payment during the financial year. Operating results in which the earnings per share improved from negative 0.84 cents/share in FY17 to 0.73 cents/share in FY 2018. At the end of financial year, the cash and cash equivalents were at $9,858,977 representing decent balance sheet position. As at October 9, 2018, the stock of MGC Pharmaceutical traded at a market price of $0.051 and has seen a performance change of a 21.43% over the last twelve months period.

THE A2 MILK COMPANY LIMITED (ASX: A2M) – EBITDA stood at $283 Mn in FY18 marking an impressive growth of 101% against prior corresponding period. The company’s ability increasing its investment in the business while leverage its fixed costs is reflected in the growing revenue result. Compared to a profit of $90.6 Mn in FY17, the company recorded net profit after tax of $195.7 Mn in FY18 which is a substantial number. The FY 18 revenue saw a rise of 68% at NZ $923 million. While basic earnings per share (EPS) also was up at 27.0 cents from 12.7 cents in the pcp. Cash on hand is of NZ$ 340.5 million which reflects strong NPAT contribution and efficient working capital. As at October 9, 2018, the stock of A2M Milk traded at a market price of $9.315 and has seen a performance change of around 43.22% over the last twelve months period.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report